PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses
Study Details
Study Description
Brief Summary
In more than 40 % of multiple sclerosis (MS) patients experiencing relapse, residual disability accumulates in spite of steroid treatment. Plasma exchanges are frequently used but there is no established evidence of their efficacy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Multiple sclerosis (MS) relapses are usually treated by steroids but some patients did not respond well to this treatment. In more than 40 % of MS patients experiencing relapses, residual disability accumulates in spite of steroid treatment and did not recover. Plasma exchanges (PE) are frequently used to treat the severe attacks of inflammatory demyelination in the central nervous system resistant to steroids (Tumani, 2008). This strategy has been evaluated so far only in few studies. Only one randomized controlled study has been performed (Weinshenker et al, 1999) including patients with very severe attacks of inflammatory demyelinating diseases of various origin (MS, acute transverse myelitis, acute disseminated encephalomyelitis, neuromyelitis optica), not improved after a treatment by steroids. A moderate or important improvement of incapacity was observed in 8 cases out of 19 (42.1%) after treatment by PE against 1 out of 17 (5.9%) after sham treatment. This study concerned only 12 patients having a relapse of MS. Based on this first controlled study and the experience of treatment of 42 MS patients in the department of Neurology of the University Hospital Pellegrin (CHU de Bordeaux) we designed a randomized controlled study of PE against sham PE in moderate to severe acute exacerbations of MS not responding to steroid treatment.
The purpose is to compare plasma exchanges versus sham exchanges on residual disability in MS patients with a demyelinating inflammatory episode (MS or syndrome with high risk of MS) experiencing a disabling relapse not improved after steroid treatment. The primary end-point will be evaluated one month after start of therapy. Secondary endpoints include safety and evaluation of improvement at 3 and 6 months and evaluation of safety
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: plasma exchange 6 plasma exchanges during 2 weeks after randomization |
Procedure: plasma exchange
6 plasma exchange each 48 hours during 2 weeks after randomization
|
| Sham Comparator: sham exchange 6 sham plasma exchanges during 2 weeks after randomization |
Procedure: sham exchanges procedure
6 sham exchanges each 48 hours during 2 weeks after randomization
|
Outcome Measures
Primary Outcome Measures
- 4 graded-scale of improvement based on objective scales and functional assessment after 1 month [after 1 month]
Secondary Outcome Measures
- 4 graded-scale of improvement based on objective scales and functional assessment [after 3 months and 6 months]
- change in functional evaluation by visual analogic scales (VAS) [after 1 month, 3 and 6 months]
- change in functional scores (kurtzke FS) [after 1 month, 3 and 6 months]
- change of EDSS scores [after 1 month, 3 and 6 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Probable relapsing-remitting MS (RRMS) according to Polman et al criteria 2010. or clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS).
-
Age 18-65
-
EDSS before the current relapse <6.5
-
Acute relapse (optic neuritis, motor pyramidal relapse, cerebellar relapse, oculomotor relapse) since less than 2 months
-
Having been treated by IV or orally steroid (Methylprednisolone, 1g/d for at least 3 days), followed or not by oral tapering.
-
The current relapse inducing a significant clinical deterioration as compared to pre-relapse status and persisting 30 days after starting steroids.
-
Loss of visual acuity more than 30% on one ot both eyes;
-
Or: increase of 1 point pyramidal or brainstem functional system score (FSS) (if score ≥ 3) or cerebellar FSS (if score ≥ 2).
-
Or: reduced walking distance associated with an increase ≥ 0.5 point EDSS if EDSS ≥4.0;
-
Having signed informed consent.
-
affiliated to the French Social Security
Exclusion Criteria:
-
Infection
-
Improving relapse.
-
Other disease interfering with evaluation.
-
Current treatment by immunosuppressive drug (as cyclophosphamide and mitoxantrone) or interrupted for less than 3 months.
-
Modification of DMT since less than 1 month.
-
Physical or psychic disease interfering with evaluation or consent.
-
Participation to another trial in the last 3 months.
-
Inability to establish peripheral central intravenous access;
-
Cerebral, autonomic, cardiac or other conditions with increased risk from hypovolemia
-
Pregnancy or breast-feeding.
-
Woman in age to procreate without effective contraception
-
Treatment by monoclonal antibody.
-
Progressive course of MS.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Service de Neurologie - Hôpital Pellegrin - CHU de Bordeaux | Bordeaux | France | 33000 | |
| 2 | Service de neurologie - CHU de Clermont-Ferrand | Clermont-Ferrand | France | ||
| 3 | Service de Neurologie - CHRU de Lille | Lille | France | 59000 | |
| 4 | Service de Neurologie - CHU de nancy | Nancy | France | 54000 | |
| 5 | Service de neurologie - CHU de Nantes | Nantes | France | 44000 | |
| 6 | Service de Neurologie - CHU de Starsbourg | Strasbourg | France | 67000 |
Sponsors and Collaborators
- University Hospital, Bordeaux
Investigators
- Study Chair: Linda WITTKOP, MD PhD, university bordeaux hospital
- Study Director: Bruno BROCHET, MD, University Hospital Bordeaux, France
- Principal Investigator: Bruno BROCHET, MD, University Hospital Bordeaux, France
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHUBX 2010/46